CY1106103T1 - Μεθοδος διαχωρισμου παραλλαγων ροταϊου και ζωντανο εξασθενημενο εμβολιο ροταϊου - Google Patents

Μεθοδος διαχωρισμου παραλλαγων ροταϊου και ζωντανο εξασθενημενο εμβολιο ροταϊου

Info

Publication number
CY1106103T1
CY1106103T1 CY20061100784T CY061100784T CY1106103T1 CY 1106103 T1 CY1106103 T1 CY 1106103T1 CY 20061100784 T CY20061100784 T CY 20061100784T CY 061100784 T CY061100784 T CY 061100784T CY 1106103 T1 CY1106103 T1 CY 1106103T1
Authority
CY
Cyprus
Prior art keywords
rotai
vaccine
variants
separation
live attenuated
Prior art date
Application number
CY20061100784T
Other languages
English (en)
Inventor
Brigette Desiree A. COLAU
Francoise Denamur
Isabelle Knott
Annick Poliszczak
Georges Thiry
Vincent Vande Velde
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9919468.0A external-priority patent/GB9919468D0/en
Priority claimed from GBGB9927336.9A external-priority patent/GB9927336D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1106103T1 publication Critical patent/CY1106103T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η εφεύρεση παρέχει εξασθενημένο πληθυσμό ροταϊού που περιλαμβάνει μία απλή παραλλαγή ή ουσιαστικά μία απλή παραλλαγή, η οποία ορίζεται από μία αλληλουχία νουκλεοτιδίου που κωδικοποιεί τουλάχιστον μία από τις κύριες ιϊκές πρωτεΐνες που ορίζονται ως VP4 και VP7. Η εφεύρεση ιδιαιτέρως παρέχει έναν πληθυσμό ροταϊού οριζόμενο ως Ρ43. Η εφεύρεση περαιτέρω παρέχει μία νέα συνταγοποίηση για ένα εμβόλιο ροταϊού που είναι στη μορφή ενός ταχέως διαλυόμενου δισκίου για άμεση διαλυτοποίηση όταν τοποθετείται πάνω στη γλώσσα.
CY20061100784T 1999-08-17 2006-06-13 Μεθοδος διαχωρισμου παραλλαγων ροταϊου και ζωντανο εξασθενημενο εμβολιο ροταϊου CY1106103T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9919468.0A GB9919468D0 (en) 1999-08-17 1999-08-17 Vaccine
GBGB9927336.9A GB9927336D0 (en) 1999-11-18 1999-11-18 Vaccine
PCT/EP2000/007965 WO2001012797A2 (en) 1999-08-17 2000-08-15 Method of separating rotavirus variants and live attenuated rotavirus vaccine

Publications (1)

Publication Number Publication Date
CY1106103T1 true CY1106103T1 (el) 2010-07-28

Family

ID=26315853

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20061100784T CY1106103T1 (el) 1999-08-17 2006-06-13 Μεθοδος διαχωρισμου παραλλαγων ροταϊου και ζωντανο εξασθενημενο εμβολιο ροταϊου
CY200600004C CY2006004I2 (el) 1999-08-17 2006-07-28 Μεθοδος διαχωρισμου παραλλαγων ροταϊου και ζωντανο εξασθενημενο εμβολιο ροταϊου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY200600004C CY2006004I2 (el) 1999-08-17 2006-07-28 Μεθοδος διαχωρισμου παραλλαγων ροταϊου και ζωντανο εξασθενημενο εμβολιο ροταϊου

Country Status (42)

Country Link
US (4) US7285280B1 (el)
EP (1) EP1212084B1 (el)
JP (3) JP2003507040A (el)
KR (1) KR100695599B1 (el)
CN (1) CN100379451C (el)
AP (1) AP1768A (el)
AR (1) AR029643A1 (el)
AT (1) ATE327765T1 (el)
AU (1) AU767885B2 (el)
BG (1) BG65314B1 (el)
BR (1) BRPI0013357B8 (el)
CA (1) CA2379196C (el)
CO (1) CO5580165A1 (el)
CY (2) CY1106103T1 (el)
CZ (1) CZ302173B6 (el)
DE (2) DE60028390T2 (el)
DK (1) DK1212084T3 (el)
DZ (1) DZ3219A1 (el)
EA (1) EA005952B1 (el)
ES (1) ES2260046T3 (el)
FR (1) FR06C0018I2 (el)
HK (1) HK1046860B (el)
HU (2) HU228975B1 (el)
IL (3) IL147926A0 (el)
LU (1) LU91251I2 (el)
MA (1) MA25489A1 (el)
MX (1) MXPA02001648A (el)
MY (1) MY133158A (el)
NL (1) NL300233I2 (el)
NO (2) NO328112B1 (el)
NZ (1) NZ517131A (el)
OA (1) OA12312A (el)
PE (1) PE20010487A1 (el)
PL (1) PL205550B1 (el)
PT (1) PT1212084E (el)
SI (1) SI1212084T1 (el)
SK (1) SK287261B6 (el)
TR (1) TR200200420T2 (el)
TW (1) TWI283270B (el)
UA (1) UA77388C2 (el)
UY (1) UY26297A1 (el)
WO (1) WO2001012797A2 (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE327765T1 (de) * 1999-08-17 2006-06-15 Glaxosmithkline Biolog Sa Methoden um rotavirusvarianten zu trennen und lebender attenuierter rotavirus impfstoff
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
GB0020089D0 (en) * 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
KR20030026654A (ko) * 2001-09-26 2003-04-03 주식회사 씨트리 인간 로타바이러스의 활성을 저해하는 항체의 생산용 항원및 그의 제조방법과 이용
GB0414787D0 (en) 2004-07-01 2004-08-04 Glaxosmithkline Biolog Sa Method
WO2005021033A2 (en) * 2003-09-02 2005-03-10 Glaxosmithkline Biologicals S.A. Vaccine
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
US20090028828A1 (en) * 2005-08-17 2009-01-29 Glaxosmithkline Biologicals Sa Rotavirus Vaccine Inducing Heterotypic Cross Protection
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
KR101051986B1 (ko) * 2006-09-28 2011-07-26 중앙대학교 산학협력단 인간로타바이러스 및 이를 이용한 백신 조성물
NZ576563A (en) 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods
EP2236617A1 (en) 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
CA3121471A1 (en) 2009-05-12 2010-11-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention New human rotavirus strains and vaccines
US9598676B2 (en) 2009-07-13 2017-03-21 Bharat Biotech International Limited Composition useful as rotavirus vaccine and a method therefor
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
BR112014026407B1 (pt) 2012-04-23 2020-12-22 Bharat Biotech International Limited formulação de vacina líquida
WO2014032082A1 (en) * 2012-08-27 2014-03-06 Murdoch Childrens Research Institute Modified human rotaviruses and uses therefor
LT3299384T (lt) * 2015-05-21 2021-12-27 Xiamen University Sutrumpintas rotaviruso vp4 baltymas ir jo pritaikymas
CN108431214B (zh) 2015-10-05 2022-03-01 美国政府(由卫生和人类服务部的部长所代表) 人轮状病毒g9p[6]毒株和作为疫苗的用途
WO2017081110A1 (en) * 2015-11-09 2017-05-18 Curevac Ag Rotavirus vaccines
JP2019502685A (ja) * 2015-12-18 2019-01-31 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 熱安定性ロタウイルスワクチン製剤およびその使用方法
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
CN110856493B (zh) * 2018-08-20 2022-02-25 中国烟草总公司黑龙江省公司牡丹江烟草科学研究所 一种植物病毒弱毒疫苗组合物、弱毒疫苗保存方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5927323B2 (ja) * 1976-10-12 1984-07-05 花王株式会社 歯みがき組成物
US4341763A (en) * 1981-03-10 1982-07-27 Smithkline-Rit Methods of vaccinating humans against rotavirus infection
US4571385A (en) 1983-06-27 1986-02-18 The United States Of America As Represented By The Department Of Health And Human Services Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
EP0152295B1 (en) * 1984-02-09 1991-03-20 Royal Children's Hospital Research Foundation Live attenuated human rotavirus vaccine and preparation thereof
US5626851A (en) * 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
KR0171434B1 (ko) 1990-11-16 1999-02-01 윌리엄 케이. 슈버트 인체 로타바이러스, 백신 및 방법
US5471385A (en) * 1992-05-21 1995-11-28 Tsubakimoto Chain Co. Routeless guiding method for moving body
US5773009A (en) * 1994-04-15 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services Rotavirus strain G9P11
US7150984B2 (en) * 1994-07-11 2006-12-19 The United States Of America As Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
AU739916B2 (en) * 1996-09-26 2001-10-25 Merck Sharp & Dohme Corp. Rotavirus vaccine formulations
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
ATE327765T1 (de) * 1999-08-17 2006-06-15 Glaxosmithkline Biolog Sa Methoden um rotavirusvarianten zu trennen und lebender attenuierter rotavirus impfstoff

Also Published As

Publication number Publication date
EA200200142A1 (ru) 2002-08-29
US7790180B2 (en) 2010-09-07
JP2007319164A (ja) 2007-12-13
BRPI0013357B8 (pt) 2021-05-25
IL147926A0 (en) 2002-08-14
IL188686A0 (en) 2008-04-13
AU6996100A (en) 2001-03-13
CY2006004I1 (el) 2009-11-04
TWI283270B (en) 2007-07-01
DE60028390T2 (de) 2006-11-02
EA005952B1 (ru) 2005-08-25
UY26297A1 (es) 2001-03-16
CZ2002522A3 (cs) 2002-05-15
MA25489A1 (fr) 2002-07-01
WO2001012797A2 (en) 2001-02-22
PE20010487A1 (es) 2001-06-23
US7790179B2 (en) 2010-09-07
NO20020763D0 (no) 2002-02-15
DE122006000026I1 (de) 2006-10-12
US20080057082A1 (en) 2008-03-06
DZ3219A1 (fr) 2001-02-22
AP1768A (en) 2007-08-16
HK1046860A1 (en) 2003-01-30
JP5474720B2 (ja) 2014-04-16
DE60028390D1 (de) 2006-07-06
SI1212084T1 (sl) 2006-08-31
HUS1300072I1 (hu) 2019-11-28
ATE327765T1 (de) 2006-06-15
OA12312A (en) 2006-05-12
UA77388C2 (uk) 2006-12-15
US20080063662A1 (en) 2008-03-13
CN100379451C (zh) 2008-04-09
BG106417A (en) 2003-04-30
CO5580165A1 (es) 2005-11-30
DK1212084T3 (da) 2006-07-10
PL205550B1 (pl) 2010-04-30
CN1379683A (zh) 2002-11-13
EP1212084A2 (en) 2002-06-12
HK1046860B (zh) 2006-10-06
US7285280B1 (en) 2007-10-23
ES2260046T3 (es) 2006-11-01
NL300233I1 (nl) 2006-09-01
PL354135A1 (en) 2003-12-29
TR200200420T2 (tr) 2002-05-21
MY133158A (en) 2007-10-31
EP1212084B1 (en) 2006-05-31
WO2001012797A3 (en) 2001-08-02
CY2006004I2 (el) 2009-11-04
NL300233I2 (nl) 2006-10-02
BRPI0013357B1 (pt) 2016-08-02
AP2002002424A0 (en) 2002-03-31
KR20020092344A (ko) 2002-12-11
NO328112B1 (no) 2009-12-07
KR100695599B1 (ko) 2007-03-14
FR06C0018I1 (el) 2006-07-21
NO2010011I2 (no) 2015-02-02
SK2432002A3 (en) 2002-09-10
NZ517131A (en) 2003-07-25
IL147926A (en) 2008-03-20
AU767885B2 (en) 2003-11-27
HU228975B1 (en) 2013-07-29
FR06C0018I2 (fr) 2007-04-27
LU91251I2 (fr) 2006-08-14
CA2379196C (en) 2015-05-26
HUP0203335A1 (hu) 2003-02-28
US20090130145A1 (en) 2009-05-21
HUP0203335A3 (en) 2004-07-28
BG65314B1 (bg) 2008-01-31
CA2379196A1 (en) 2001-02-22
MXPA02001648A (es) 2002-08-06
JP2003507040A (ja) 2003-02-25
JP2011045374A (ja) 2011-03-10
LU91251I9 (el) 2018-12-31
CZ302173B6 (cs) 2010-11-24
NO20020763L (no) 2002-04-16
SK287261B6 (sk) 2010-04-07
BR0013357A (pt) 2002-04-30
PT1212084E (pt) 2006-07-31
AR029643A1 (es) 2003-07-10
NO2010011I1 (no) 2010-06-07

Similar Documents

Publication Publication Date Title
CY1106103T1 (el) Μεθοδος διαχωρισμου παραλλαγων ροταϊου και ζωντανο εξασθενημενο εμβολιο ροταϊου
CY1105684T1 (el) Ανοσοενισχυτικα εμβολιων
ATE466084T1 (de) Hla-a24-restringiertes krebsantigenpeptid
DZ2462A1 (fr) Vaccin antigrippal.
NL300415I1 (nl) Vaccin tegen antigenen van bacteriën
NO20015073L (no) Vaksiner
ES2244617T3 (es) Vacunas a base de salmonelas en las cuales los genes ssa han sido inactivados.
ATE270707T1 (de) Entepneumovirus und entsprechendes impfstoff
CY1112658T1 (el) Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d
PT1047446E (pt) Composicao vacinica para o virus herpes simplex e metodos de utilizacao
BR9704879A (pt) Composição de vacina e uso de um vírus cav vivo
HU0000362D0 (en) Novel antigenic class of avian reoviruses
CY1107560T1 (el) Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
CY1109976T1 (el) Μεθοδος διαχωρισμου παραλλαγων ροταϊου και ζωντανο εξασθενημενο εμβολιο ροταϊου
IT1309584B1 (it) Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
DE69922804D1 (de) Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien
DK0493575T3 (da) Vaccine af reassortant rotavirus
FR2796282B1 (fr) Vaccin inactive contre la calicivirose feline
CY1117601T1 (el) Ανασυνδυασμενα εμβολια κατα κωπηποδων καλιγιδων (θαλασσιων ψειρων) και αλληλουχιες αντιγονων αυτων
IT1314233B1 (it) Vaccino per hiv.
ZA200003499B (en) A recombinant Necastle disease virus as an embryo vaccine.
FR2698271B1 (fr) Vaccin contre le virus de la leucémie bovine, nouveau peptide immunogène et kit de vaccination.